EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Transapical Mitral Valve Replacement

Michaela M Hell, Mirjam G Wild, Stephan Baldus, Tanja Rudolph, Hendrik Treede, Anna Sonia Petronio, Thomas Modine, Martin Andreas, Augustin Coisne, Alison Duncan, Luis Nombela Franco, Fabien Praz und 16 weitere

JACC: Cardiovascular Interventions · 2024-03 · 17 (5) · 648-661

DOI: 10.1016/j.jcin.2023.12.027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Cardiovascular Interventions, 2024-03. Verfasst von Michaela M Hell und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Medical Center Mainz, Mainz, Germany. Hauptthemen laut MEDLINE: Heart Valve Prosthesis Implantation, Heart Valve Prosthesis, Mitral Valve Insufficiency. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Early studies of the Tendyne transcatheter mitral valve replacement (TMVR) showed promising results in a small selective cohort. OBJECTIVES: The authors present 1-year data from the currently largest commercial, real-world cohort originating from the investigator-initiated TENDER (Tendyne European Experience) registry. METHODS: All patients from the TENDER registry eligible for 1-year follow-up were included. The primary safety endpoint was 1-year cardiovascular mortality. Primary performance endpoint was reduction of mitral regurgitation (MR) up to 1 year. RESULTS: Among 195 eligible patients undergoing TMVR (median age 77 years [Q1-Q3: 71-81 years], 60% men, median Society of Thoracic Surgeons Predicted Risk of Mortality 5.6% [Q1-Q3: 3.6%-8.9%], 81% in NYHA functional class III or IV, 94% with MR 3+/4+), 31% had "real-world" indications for TMVR (severe mitral annular calcification, prior mitral valve treatment, or others) outside of the instructions for use. The technical success rate was 95%. The cardiovascular mortality rate was 7% at 30 day and 17% at 1 year (all-cause mortality rates were 9% and 29%, respectively). Reintervention or surgery following discharge was 4%, while rates of heart failure hospitalization reduced from 68% in the preceding year to 25% during 1-year follow-up. Durable MR reduction to ≤1+ was achieved in 98% of patients, and at 1 year, 83% were in NYHA functional class I or II. There was no difference in survival and major adverse events between on-label use and "real-world" indications up to 1 year. CONCLUSIONS: This large, real-world, observational registry reports high technical success, durable and complete MR elimination, significant clinical benefits, and a 1-year cardiovascular mortality rate of 17% after Tendyne TMVR. Outcomes were comparable between on-label use and "real-world" indications, offering a safe and efficacious treatment option for patients without alternative treatments. (Tendyne European Experience Registry [TENDER]; NCT04898335).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart Valve Prosthesis ImplantationHeart Valve ProsthesisMitral Valve InsufficiencyMaleHumansAgedFemaleMitral ValveTreatment OutcomeCardiac CatheterizationRegistries

Stichwörter der Autor:innen

mitral annular calcificationmitral regurgitationmitral valvetranscatheter mitral valve replacement

Autor:innen und Institutionen

  • Department of Cardiology, University Medical Center Mainz, Mainz, Germany.
  • Medizinische Klinik I, LMU University Hospital, Munich, Germany.
  • Department of Cardiology, Heart Center, University Hospital Cologne, Cologne, Germany.
  • Department of Cardiology, Heart- und Diabetes Center Northrhine-Westfalia, Bad Oeynhausen, Ruhr-University Bochum, Bochum, Germany.
  • Department of Cardiovascular Surgery, Universitätsmedizin Mainz of the Johannes Gutenberg University, Mainz, Germany.
  • Cardiothoracic and Vascular Department, University of Pisa, Pisa, Italy.

Zitieren

APA

Hell, M. M., Wild, M. G., Baldus, S., Rudolph, T., Treede, H., Petronio, A. S., Modine, T., Andreas, M., Coisne, A., Duncan, A., Franco, L. N., Praz, F., Ruge, H., Conradi, L., Zierer, A., Anselmi, A., Dumonteil, N., Nickenig, G., Piñón, M., …, & TENDER Investigators (2024). Transapical Mitral Valve Replacement. JACC: Cardiovascular Interventions, 17(5), 648-661. https://doi.org/10.1016/j.jcin.2023.12.027

Vancouver

Hell MM, Wild MG, Baldus S, Rudolph T, Treede H, Petronio AS, et al. Transapical Mitral Valve Replacement. JACC: Cardiovascular Interventions. 2024;17(5):648-661. doi:10.1016/j.jcin.2023.12.027

BibTeX
@article{Hell2024,
  author = {Hell, Michaela M and Wild, Mirjam G and Baldus, Stephan and Rudolph, Tanja and Treede, Hendrik and Petronio, Anna Sonia and Modine, Thomas and Andreas, Martin and Coisne, Augustin and Duncan, Alison and Franco, Luis Nombela and Praz, Fabien and Ruge, Hendrik and Conradi, Lenard and Zierer, Andreas and Anselmi, Amedeo and Dumonteil, Nicolas and Nickenig, Georg and Piñón, Miguel and Barth, Sebastian and Adamo, Marianna and Dubois, Christophe and Torracca, Lucia and Maisano, Francesco and Lurz, Philipp and von Bardeleben, Ralph Stephan and Hausleiter, Jörg and TENDER Investigators, TENDER Investigators},
  title = {Transapical Mitral Valve Replacement},
  journal = {JACC: Cardiovascular Interventions},
  year = {2024},
  volume = {17},
  number = {5},
  pages = {648--661},
  doi = {10.1016/j.jcin.2023.12.027}
}
Kostenlos starten →